ArticlePloS one2014
HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 173 citations in OpenAlex.
- Racial disparities in colorectal cancer clinicopathological and molecular tumor characteristics: a systematic review.Cancer causes & control : CCC · 2024Pooled it
- Systematic literature review and meta-analysis of HER2 amplification, overexpression, and positivity in colorectal cancer.JNCI cancer spectrum · 2024Pooled it
- Pertuzumab Plus Trastuzumab for Treatment-RefractoryJCO clinical cancer informatics · 2022Trial
- Assessment of a HER2 scoring system for colorectal cancer: results from a validation study.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2015Trial
- Prognostic and Treatment-Specific Predictive Implications of HER2 Expression in RAS Wild-Type Metastatic Colorectal Cancer: A Multicenter Retrospective Real-World Study.Journal of clinical medicine · 2026Article
- A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review.Frontiers in oncology · 2025Article
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.Clinical & experimental metastasis · 2024Article
- Prognostic and Predictive Roles of HER2 Status in Non-Breast and Non-Gastroesophageal Carcinomas.Cancers · 2024Review
- HER2-targeted therapies beyond breast cancer - an update.Nature reviews. Clinical oncology · 2024Review
- Therapeutic strategies targeting the epidermal growth factor receptor signaling pathway in metastatic colorectal cancer.World journal of gastrointestinal oncology · 2024Review
- HER2-neu Expression and Survival in Colorectal Cancer in the South of Egypt; Immunohistochemistry and Genetic Study.Asian Pacific journal of cancer prevention : APJCP · 2024Article
- RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification.Scientific reports · 2024Article
- Review
- Learning Outcomes of "GetSMART," Education for Diagnostics and Targeted Treatment for HER2+ Metastatic Gastric and Colorectal Cancers.Journal of cancer education : the official journal of the American Association for Cancer Education · 2024Article
- Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future.ESMO gastrointestinal oncology · 2024Review
- HER2-targeted therapies in cancer: a systematic review.Biomarker research · 2024Review
- Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.Cancers · 2024Review
- Gastrointestinal Malignancy: Genetic Implications to Clinical Applications.Cancer treatment and research · 2024Review
- A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.British journal of cancer · 2023Article
- Molecular subtyping in colorectal cancer: A bridge to personalized therapy (Review).Oncology letters · 2023Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed at determining the incidence and clinical implications of HER2 status in primary colorectal cancer (CRC). HER2 status was investigated in two retrospective cohorts of 365 consecutive CRC patients (cohort 1) and 174 advanced CRC patients with synchronous or metachronous distant metastasis (cohort 2). HER2 status was determined by performing dual-color silver in-situ hybridization (SISH), mRNA in-situ hybridization (ISH), and immunohistochemistry (IHC). The incidence of HER2 protein overexpression (IHC 2+/3+) was approximately 6% (22 of 365 in cohort 1; 10 of 174 in cohort 2). HER2 gene amplification was observed in 5.8% of the patients from cohort 1 and 6.3% of the patients from cohort 2. HER2 gene amplification was more frequently observed in CRCs located in the rectum than in the right and left colon (P = 0.013 in cohort 1; P = 0.009 in cohort 2). HER2 status, determined by IHC, ISH, and dual-color SISH, was not significantly associated with aggressive CRC behaviour or patients' prognosis in both the cohorts. Of the combined cohort with a total of 539 cases, the concordance rate was 95.5% between dual-color SISH and IHC detection methods. On excluding equivocally immunostained cases (IHC 2+), the concordance rate was 97.7%. HER2 mRNA overtranscription, detected by ISH, significantly correlated with protein overexpression and gene amplification (P<0.001). HER2 gene amplification was identified in a minority of CRC patients with high concordance rates between dual-color SISH and IHC detection methods. Although HER2 status did not predict patients' prognosis, our findings may serve as a basis for future studies on patient selection for HER2 targeted therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.